In this issue of Insights, we summarize a recent discussion held with a number of pharmaceutical companies on US health policy, potential priorities for the Trump administration, and yes, pricing. Tim Wilsdon, an expert in international policy issues affecting the development and commercialization of medicines, led the discussion.
To read more, click the link below.
Assessing the economic case for Alzheimer’s disease policy prioritisation
The analysis has highlighted specific areas where more urgent action is needed, specifically: Accelerating diagnosing patients at scale; Supporting expansion...